Search results for " Specialist"

showing 10 items of 770 documents

Propranolol and infantile hemangiomas: Outcome from a tricentric study.

2020

Introduction: The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors. Cases presenting with ulceration, functional limitation, and visceral or life-threatening localization are excellent indications to medical therapy. The aim was to report the medium term follow-up after the introduction of propranolol in 3 referral centers with particular attention to outcome and surgical treatments. Materials and methods: In the period 2011-2018 348 patients underwent systemic therapy with propanolol at a mean age of 3.5 months (range 1-10). The indications to begin the treatment were: visceral localization (10,6%), ulceration (2…

Settore MED/38 - Pediatria Generale E SpecialisticaInfantile hemangioma; Laser; Propranolol; SurgerySettore MED/20 - Chirurgia Pediatrica E InfantileLaserSurgeryPropranololInfantile hemangioma Laser Propranolol SurgeryInfantile hemangiomaJournal of plastic, reconstructiveaesthetic surgery : JPRAS
researchProduct

Terapia con inibitori dell'IL-1 in pazienti con mutazioni di malattie autoinfiammatorie a bassa penetranza: una casistica dall'età pediatrica al giov…

2017

Settore MED/38 - Pediatria Generale E SpecialisticaInibitori dell'IL-1 malattie autoinfiammatorie bassa penetranza
researchProduct

Iperinsulinismo congenito da mutazione in omozigosi di INS-R: descrizione di un caso

2014

Settore MED/38 - Pediatria Generale E SpecialisticaIperinsulinismo congenito omozigosi INS-r
researchProduct

L’ADOLESCENTE CON IPOGONADISMO IPOGONADOTROPO: LA CENTRALITA’ DEL RUOLO DEL PEDIATRA

2009

Settore MED/38 - Pediatria Generale E SpecialisticaIpogonadismo ipogonadotropo obesità ipofisi
researchProduct

DEVELOPMENT AND INITIAL VALIDATION OF THE SYSTEMIC JADAS, A NEW COMPOSITE DISEASE ACTIVITY SCORE FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

2019

Background: Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile idiopathic arthritis (JIA). However, so far the JADAS has been validated only in children with the non-systemic categories of JIA. Objectives: To develop and validate the systemic JADAS (sJADAS), a new version of the JADAS specific to systemic JIA (sJIA). Methods: The sJADAS is made up by adding a fifth item, named Systemic Manifestation Score (SMS), to the four items included in the original tool (physician global assessment of disease activity, parent/patient global assessment of well-being, active joint count and ery…

Settore MED/38 - Pediatria Generale E SpecialisticaJADAS Juvenile Idiopathic Arthritis disease activity
researchProduct

ASSESSING THE CLINICAL RELEVANCE AND RISK MINIMIZATION OF ANTIBODIES TO BIOLOGICS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) (ABIRISK) - PRELIMINARY RESU…

2018

Introduction: ABIRISK is a project funded by Innovative Medicine Initiative, with the aim to investigate anti-drug antibody (ADA) formation in the treatment of JIA with biologics (BPs). A major limitation to the use of biologics is the development of ADA that may decrease the efficacy of BPs. Objectives: The aim of this project is to improve the capability to predict biologic immunogenicity in JIA patients. Methods: JIA Patients (by ILAR criteria) followed by 24 PRINTO centres in 12 countries were prospectively enrolled and treated with Etanercept, Adalimumab or Tocilizumab. Patient’s data were obtained from Pharmachild, a pharmacovigilance data registry of JIA patients. For each patient de…

Settore MED/38 - Pediatria Generale E SpecialisticaJIA ABIRISK
researchProduct

EVALUATION OF THE DISEASE COURSE OF ITALIAN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH ETANERCEPT: PRELIMINARY RESULTS IN 1019 PATIENTS

2015

Methods: This is a multicenter, observational study that includes all children with JIA who were given ETN at Italian pediatric rheumatology centers after January 2000. Patients were classified in 2 groups: patients who were no longer taking ETN at study start (Group 1); patients who were still receiving ETN at study start (Group 2). Patients in Group 1 underwent only retrospective assessments, whereas patients in Group 2 underwent both retrospective and cross-sectional assessments. The primary outcome of the study were reasons for ETN discontinuation in patients in Group 1, and achievement of the states of inactive disease (ID), minimal disease activity (MDA) and parent- and child-acceptab…

Settore MED/38 - Pediatria Generale E SpecialisticaJUVENILE IDIOPATHIC ARTHRITIS ETANERCEPT JADAS
researchProduct

JUVENILE IDIOPATHIC ARTHRITIS AND FITNESS: A TEAMWORK

2018

Introduction: Patients with Juvenile Idiopathic Arthritis (JIA) have limited fitness and reduced aerobic and anaerobic exercise capacity vs. healthy peers. Furthermore, low intensity exercise programs are safe in children with JIA and may improve fitness, joint excursion and quality of life, reduce pain, fatigue and the employ to antiinflammatory drugs. Objectives: The purpose of the study was to evaluate postural and balance deficits and fitness with specific test battery in children and adolescents affected by JIA. Methods: We enrolled 30 patients with JIA (13 M; 17 F; age: 8-18 years); among those, 7 were evaluated longitudinally in the period 2016-2018, comparing the tests in different …

Settore MED/38 - Pediatria Generale E SpecialisticaJUVENILE IDIOPATHIC ARTHRITIS FITNESS
researchProduct

Infliximab administration effective in the treatment of refractory Kawasaki Disease

2010

Settore MED/38 - Pediatria Generale E SpecialisticaKawasaki DiseaseInfliximab
researchProduct

TRATTAMENTO CON INFLIXIMAB IN UN LATTANTE CON MALATTIA DI KAWASAKI RESISTENTE ALLE TERAPIE CONVENZIONALI

2009

Settore MED/38 - Pediatria Generale E SpecialisticaKawasaki INFLIXIMAB lattante
researchProduct